SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Drug Delivery System

PUBLISHER: Meticulous Research | PRODUCT CODE: 2132830

Cover Image

PUBLISHER: Meticulous Research | PRODUCT CODE: 2132830

Targeted Drug Delivery Market Size, Share & Trends Analysis, by Technology, Application, End User, and Geography - Global Forecast to 2036

PUBLISHED:
PAGES: 259 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF & Excel (Single User License)
USD 4175
PDF & Excel (Multi User License)
USD 5875
PDF & Excel (Global Site License)
USD 7875

Add to Cart

Description

Table of Contents

List of Tables

The global Targeted Drug Delivery Market was valued at USD 25.96 billion in 2025. It is estimated to reach USD 32.00 billion in 2026 and is projected to grow to USD 73.07 billion by 2036, at a CAGR of 8.6% during the forecast period. This report offers a detailed look at the market, covering key trends, technology developments, approved products and pipelines, competitive activity, and future growth opportunities.

Targeted drug delivery uses a carrier or conjugate to send a drug mainly to specific tissues, cells, or sites inside cells. This increases the amount of drug that reaches the disease while reducing exposure to healthy tissue. The market includes antibody-drug conjugates (ADCs), ligand-conjugated oligonucleotides such as GalNAc-siRNA, lipid nanoparticle therapies, liposomal drugs, polymeric and protein-based nanoparticles, and other targeted carriers. These products are now standard treatments in breast, urothelial, lung, and blood cancers, as well as in several rare and cardiometabolic diseases.

Sales of leading targeted delivery products are rising across technologies. Roche's Polivy sales grew 38% to CHF 1.5 billion in 2025, Gilead's Trodelvy reached USD 1.4 billion, and AbbVie's Elahere generated USD 690 million. In RNA therapeutics, Alnylam's net product revenues rose 81% to USD 2,987 million, driven by AMVUTTRA after its U.S. approval for transthyretin amyloid cardiomyopathy. New approvals in 2025 and 2026, including Blenrep, REDEMPLO, and new breast cancer indications for Enhertu and Datroway, together with Novartis's roughly USD 12 billion acquisition of Avidity Biosciences, show how quickly the field is expanding.

The report examines targeting approaches, approved products and pipelines, regulations, pricing and reimbursement, manufacturing and the CDMO landscape, and competitive strategies. It explains how new ADC payloads, bispecific ADCs, GalNAc conjugates, and lipid nanoparticles are opening up new treatment areas beyond cancer. It also provides market forecasts, segment-level insights, and regional analysis across 5 regions and 25 countries and sub-regions to support business, investment, and product decisions.

Market Dynamics

Regulators have now approved a growing list of antibody-drug conjugates across solid tumors and blood cancers, including Enhertu, Kadcyla, Polivy, Padcev, Adcetris, Trodelvy, Elahere, and Blenrep. Each approval makes it easier for later products to follow and encourages further investment in the technology. RNA therapeutics delivered through GalNAc conjugates and lipid nanoparticles have also proven themselves both clinically and commercially, with products such as AMVUTTRA and Leqvio showing that infrequent dosing can work in large patient groups. The rising global cancer burden, with 20.6 million new cancer cases in 2024, continues to support demand for precise oncology treatments, and a growing pipeline of biologics and nucleic acid drugs is adding further momentum.

Making antibody-drug conjugates and nanoparticle formulations is complex and expensive, requiring specialized facilities for handling highly potent drugs, precise conjugation chemistry, and strict quality control. These costs feed into high product prices, which draw close scrutiny from payers and health technology assessment bodies, especially in Europe. Developers also face scientific risks related to payload stability, linker chemistry, toxicity, and immune reactions, and regulatory setbacks such as the withdrawal of Trodelvy's bladder cancer indication show that these risks can affect even approved products. In addition, commercial-scale manufacturing capacity for complex conjugates and nanoparticles remains limited.

Targeted delivery platforms are moving beyond the liver and cancer into cardiovascular, central nervous system, and other tissues, which could greatly expand the number of patients who can benefit. New ADC payloads, bispecific ADCs, and novel targets offer ways to improve effectiveness and overcome resistance to current treatments. Orphan drug incentives, including market exclusivity and faster review pathways, are also encouraging companies to develop nucleic acid therapies for rare diseases.

Segment Analysis

The report analyzes the market by technology, payload type, application, route of administration, end user, and geography, helping stakeholders identify the most promising growth opportunities.

Based on technology, the market is segmented into antibody-drug conjugates (ADCs), ligand-conjugated oligonucleotides (GalNAc-siRNA & antisense conjugates), lipid nanoparticle (LNP) therapeutics, liposomal drug delivery systems, polymeric & protein-based nanoparticles and micelles, and other targeted conjugates & carriers. In 2026, antibody-drug conjugates are expected to account for the largest share of the market. ADCs have a broad base of approved products in solid tumors and blood cancers, continue to gain approvals in earlier lines of treatment, and have the largest clinical pipeline of any targeted delivery technology. Ligand-conjugated oligonucleotides are expected to grow the fastest, as GalNAc-conjugated siRNA and antisense drugs move from rare diseases into large cardiovascular and metabolic patient groups, supported by products such as AMVUTTRA, Leqvio, REDEMPLO, and TRYNGOLZA.

Based on payload type, the market is segmented into cytotoxic small-molecule payloads, small interfering RNA (siRNA), antisense oligonucleotides (ASOs), mRNA & gene-editing payloads, and other payloads. In 2026, cytotoxic small-molecule payloads are expected to hold the largest share, as they are used in all commercial ADCs and in liposomal and albumin-bound cancer drugs. Antisense oligonucleotides are expected to grow the fastest among payloads with commercial sales, driven by new launches such as TRYNGOLZA, DAWNZERA, and WAINUA, while siRNA remains the largest nucleic acid payload.

Based on application, the market is segmented into oncology (solid tumors and hematologic malignancies), genetic & rare disorders, cardiovascular & metabolic diseases, infectious diseases, central nervous system disorders, and other applications. In 2026, oncology is expected to hold the largest share, as most approved ADCs, liposomal chemotherapies, and albumin-bound nanoparticles are used in cancer. Within oncology, solid tumors account for the larger share and are expected to grow faster than blood cancers. The cardiovascular & metabolic diseases segment is expected to grow the fastest, supported by AMVUTTRA in transthyretin amyloid cardiomyopathy, Leqvio in high cholesterol, and late-stage siRNA and antisense programs in hypertension, lipid disorders, and lipoprotein(a)-related heart disease.

Based on route of administration, the market is segmented into intravenous, subcutaneous, and other routes. In 2026, the intravenous segment is expected to hold the largest share, as all commercial ADCs and lipid nanoparticle, liposomal, and albumin-bound products are given intravenously. The subcutaneous segment is expected to grow the fastest, driven by GalNAc-conjugated siRNA and antisense drugs that need only infrequent dosing and can be given in a doctor's office or at home.

Based on end user, the market is segmented into hospitals & specialty cancer centers, ambulatory infusion centers & physician offices, and specialty pharmacies & home care settings. In 2026, hospitals & specialty cancer centers are expected to hold the largest share, since intravenous ADCs and liposomal chemotherapy require safe handling of hazardous drugs and close monitoring for side effects. Specialty pharmacies & home care settings are expected to grow the fastest, supported by the rising use of self-administered, infrequently dosed RNA therapies for chronic diseases and payer efforts to move care to lower-cost settings.

Regional Analysis

The report covers North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, spanning 25 countries and sub-regions. The regional analysis considers disease burden, regulatory approvals, pricing and reimbursement systems, national drug lists, the presence of developers and manufacturers, and access to specialty treatment centers.

In 2026, North America is expected to account for the largest share of 55.1% of the global market. The U.S. is the first and largest launch market for most ADCs and RNA therapies, offers high prices and broad coverage for specialty medicines, and is home to leading developers such as Pfizer, Gilead, AbbVie, Alnylam, Ionis, and Arrowhead. The U.S. alone is expected to account for 53.2% of the global market in 2026.

Europe holds a 24.1% share in 2026, with Germany as the largest country market, supported by centralized EMA approvals and reimbursement at launch in Germany, although national health technology assessments and cost controls slow growth. Asia-Pacific is expected to grow the fastest during the forecast period. China has become a major source of ADC innovation and has added products such as Enhertu, sacituzumab tirumotecan, and Leqvio to its national reimbursement list, while Japan leads in ADCs through Daiichi Sankyo. Japan is expected to be the largest market in the region in 2026, and China is expected to grow at a CAGR of 14.1%. Latin America and the Middle East & Africa are smaller markets, where growth depends on regulatory approvals, reimbursement, and access to specialty care.

Competitive Landscape

The report provides a detailed review of the competitive landscape, covering the market positions, targeted delivery portfolios, pipelines, technology platforms, strategic developments, and financial performance of leading companies.

A small number of product franchises account for a large share of revenue in the targeted drug delivery market, which is moderately concentrated. Based on product sales, the Daiichi Sankyo and AstraZeneca alliance behind Enhertu and Datroway ranked first in 2025, followed by F. Hoffmann-La Roche Ltd, Pfizer Inc., and Alnylam Pharmaceuticals, Inc. Beyond these leaders, many pharmaceutical and biotech companies compete through individual products, such as AbbVie's Elahere, Gilead's Trodelvy, GSK's Blenrep, and Ipsen's Onivyde, while Chinese developers such as Kelun-Biotech are quickly gaining share at home and licensing assets to global partners. Between 2023 and 2026, regulatory approvals, filings, and reimbursement listings were the most common strategies, followed by clinical and pipeline advancement, acquisitions, and licensing and partnerships. Major deals included Pfizer's acquisition of Seagen, AbbVie's acquisition of ImmunoGen, and Novartis's acquisition of Avidity Biosciences.

The competitive benchmarking compares companies on their portfolios across technologies and payload types and on their commercial and pipeline positions. Companies compete on clinical results, speed of approval in earlier lines of treatment, manufacturing capability, and access to proven delivery platforms.

Key companies profiled in the report include Daiichi Sankyo Company, Limited (Japan), AstraZeneca PLC (U.K.), F. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc. (U.S.), Astellas Pharma Inc. (Japan), Gilead Sciences, Inc. (U.S.), Takeda Pharmaceutical Company Limited (Japan), GSK plc (U.K.), Genmab A/S (Denmark), Alnylam Pharmaceuticals, Inc. (U.S.), Novartis AG (Switzerland), Ionis Pharmaceuticals, Inc. (U.S.), AbbVie Inc. (U.S.), Arrowhead Pharmaceuticals, Inc. (U.S.), Ipsen S.A. (France), Jazz Pharmaceuticals plc (Ireland), ADC Therapeutics SA (Switzerland), and Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (China).

How This Report Helps

  • Provides reliable market size estimates and long-term forecasts for the global targeted drug delivery market.
  • Explains how ADC approvals, RNA therapeutics, cancer burden, pricing pressures, and regulations affect market growth.
  • Identifies high-growth opportunities across technology, payload type, application, route of administration, end user, and region.
  • Analyzes approved products and pipelines, regulations, pricing and reimbursement, manufacturing capacity, and company strategies shaping the market.
  • Benchmarks leading companies based on their portfolios, pipelines, technology platforms, and market positions.
  • Supports product development, licensing, investment planning, partnership evaluation, market entry, and business expansion decisions.
  • Delivers practical market insights for pharmaceutical and biotechnology companies, CDMOs, technology platform developers, healthcare providers, and investors.

Key Questions Answered

  • How big is the global targeted drug delivery market today, and how will it grow through 2036?
  • What clinical, regulatory, and economic factors are driving market growth?
  • What are the main drivers, restraints, opportunities, and challenges shaping the industry?
  • Which technology, payload type, application, route of administration, end user, and regional segments will grow the fastest?
  • How are antibody-drug conjugates, GalNAc conjugates, and lipid nanoparticles expanding into new diseases beyond cancer?
  • Which regions and countries offer the most attractive business opportunities?
  • Who are the leading companies in the market, and what strategies are they following?
  • What recent approvals, acquisitions, licensing deals, and pipeline developments are shaping the competitive landscape?
  • How can stakeholders use this report to support investment decisions, product development, competitive benchmarking, and long-term strategy?
Show more
Product Code: MRHC - 1042154

TABLE OF CONTENTS

  • Table of Contents

1. Introduction

  • 1.1. Market Definition and Scope
  • 1.2. Market Ecosystem
  • 1.3. Currency and Limitations
    • 1.3.1. Currency
    • 1.3.2. Limitations
  • 1.4. Key Stakeholders

2. Research Methodology

  • 2.1. Research Approach
  • 2.2. Data Collection & Validation Process
    • 2.2.1. Secondary Research
    • 2.2.2. Primary Research & Validation
      • 2.2.2.1. Primary Interviews with Targeted Drug Delivery Experts
      • 2.2.2.2. Country-/Region-Level Analysis
  • 2.3. Market Estimation
    • 2.3.1. Bottom-Up Approach
    • 2.3.2. Top-Down Approach
    • 2.3.3. Forecast Methodology
  • 2.4. Data Triangulation
  • 2.5. Assumptions

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Targeted Drug Delivery Overview
    • 4.2.1. Concept of Targeted Drug Delivery (Payload, Carrier, Targeting Mechanism)
    • 4.2.2. Active vs. Passive Targeting
    • 4.2.3. Targeted Drug Delivery vs. Targeted Therapy
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
      • 4.3.1.1. Expanding Regulatory Approval Precedent for Antibody-Drug Conjugates
      • 4.3.1.2. Clinical and Commercial Validation of Ligand-Conjugated and Lipid Nanoparticle RNA Therapeutics
      • 4.3.1.3. Rising Global Cancer Burden Sustaining Demand for Precision Oncology Delivery Systems
      • 4.3.1.4. Growing Biologics and Nucleic Acid Therapeutic Pipeline
    • 4.3.2. Restraints
      • 4.3.2.1. High Manufacturing Complexity and Cost of Conjugation and Nanoparticle Formulation
      • 4.3.2.2. Payer Scrutiny and Health Technology Assessment Pressure on High-Cost Therapeutics
    • 4.3.3. Opportunities
      • 4.3.3.1. Extension of Targeted Delivery Platforms into Cardiovascular, CNS, and Extrahepatic Indications
      • 4.3.3.2. Next-Generation ADC Payloads, Bispecific ADCs, and Novel Targets
      • 4.3.3.3. Orphan Drug and Rare Disease Incentives Accelerating Nucleic Acid Delivery Programs
    • 4.3.4. Challenges
      • 4.3.4.1. Payload Stability, Linker Chemistry, Toxicity, and Immunogenicity Risks
      • 4.3.4.2. Limited Commercial-Scale Manufacturing Capacity for Complex Conjugates and Nanoparticles
  • 4.4. Approved Products & Pipeline Analysis
  • 4.5. Regulatory Landscape
    • 4.5.1. U.S. Regulatory Landscape
    • 4.5.2. European Regulatory Landscape
    • 4.5.3. Asia-Pacific Regulatory Landscape
    • 4.5.4. Implications for Market Participants
  • 4.6. Pricing & Reimbursement Analysis
    • 4.6.1. U.S. Pricing & Reimbursement
    • 4.6.2. European Pricing & Reimbursement
    • 4.6.3. China & Asia-Pacific Pricing & Reimbursement
    • 4.6.4. Implications for Market Growth
  • 4.7. Manufacturing & CDMO Landscape
    • 4.7.1. Manufacturing Requirements by Technology
    • 4.7.2. In-House Manufacturing Strategies
    • 4.7.3. Contract Development & Manufacturing Organizations
    • 4.7.4. Implications for Market Participants
  • 4.8. Porter's Five Forces Analysis
    • 4.8.1. Bargaining Power of Buyers
    • 4.8.2. Bargaining Power of Suppliers
    • 4.8.3. Threat of Substitutes
    • 4.8.4. Threat of New Entrants
    • 4.8.5. Degree of Competition

5. Targeted Drug Delivery Market, by Technology

  • 5.1. Introduction
  • 5.2. Antibody-Drug Conjugates (ADCs)
  • 5.3. Ligand-Conjugated Oligonucleotides (GalNAc-siRNA & Antisense Conjugates)
  • 5.4. Lipid Nanoparticle (LNP) Therapeutics
  • 5.5. Liposomal Drug Delivery Systems
  • 5.6. Polymeric & Protein-Based Nanoparticles and Micelles
  • 5.7. Other Targeted Conjugates & Carriers

6. Targeted Drug Delivery Market, by Payload Type

  • 6.1. Introduction
  • 6.2. Cytotoxic Small-Molecule Payloads
  • 6.3. Small Interfering RNA (siRNA)
  • 6.4. Antisense Oligonucleotides (ASOs)
  • 6.5. mRNA & Gene-Editing Payloads
  • 6.6. Other Payloads

7. Targeted Drug Delivery Market, by Application

  • 7.1. Introduction
  • 7.2. Oncology
    • 7.2.1. Solid Tumors
    • 7.2.2. Hematologic Malignancies
  • 7.3. Genetic & Rare Disorders
  • 7.4. Cardiovascular & Metabolic Diseases
  • 7.5. Infectious Diseases
  • 7.6. Central Nervous System Disorders
  • 7.7. Other Applications

8. Targeted Drug Delivery Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Intravenous
  • 8.3. Subcutaneous
  • 8.4. Other Routes

9. Targeted Drug Delivery Market, by End User

  • 9.1. Introduction
  • 9.2. Hospitals & Specialty Cancer Centers
  • 9.3. Ambulatory Infusion Centers & Physician Offices
  • 9.4. Specialty Pharmacies & Home Care Settings

10. Targeted Drug Delivery Market, by Geography

  • 10.1. Introduction
  • 10.2. North America
    • 10.2.1. U.S.
    • 10.2.2. Canada
  • 10.3. Europe
    • 10.3.1. Germany
    • 10.3.2. France
    • 10.3.3. U.K.
    • 10.3.4. Italy
    • 10.3.5. Spain
    • 10.3.6. Switzerland
    • 10.3.7. Netherlands
    • 10.3.8. Rest of Europe
  • 10.4. Asia-Pacific
    • 10.4.1. Japan
    • 10.4.2. China
    • 10.4.3. South Korea
    • 10.4.4. Australia
    • 10.4.5. India
    • 10.4.6. Southeast Asia
    • 10.4.7. Rest of Asia-Pacific
  • 10.5. Latin America
    • 10.5.1. Brazil
    • 10.5.2. Mexico
    • 10.5.3. Rest of Latin America
  • 10.6. Middle East & Africa
    • 10.6.1. Saudi Arabia
    • 10.6.2. U.A.E.
    • 10.6.3. Israel
    • 10.6.4. South Africa
    • 10.6.5. Rest of Middle East & Africa

11. Competitive Landscape

  • 11.1. Overview
  • 11.2. Key Growth Strategies
  • 11.3. Competitive Benchmarking
  • 11.4. Competitive Dashboard
    • 11.4.1. Market Leaders
    • 11.4.2. Market Differentiators
    • 11.4.3. Vanguards
    • 11.4.4. Emerging Players
  • 11.5. Market Ranking Analysis, by Key Player (2025)
    • 11.5.1. Daiichi Sankyo Company, Limited (Japan) & AstraZeneca PLC (U.K.) - Rank 1
    • 11.5.2. F. Hoffmann-La Roche Ltd (Switzerland) - Rank 2
    • 11.5.3. Pfizer Inc. (U.S.) - Rank 3
    • 11.5.4. Alnylam Pharmaceuticals, Inc. (U.S.) - Rank 4

12. Company Profiles

  • 12.1. Daiichi Sankyo Company, Limited
    • 12.1.1. Business Overview
    • 12.1.2. Financial Overview
    • 12.1.3. Targeted Drug Delivery Portfolio
    • 12.1.4. Pipeline
    • 12.1.5. Technology Platforms
    • 12.1.6. Strategic Developments
    • 12.1.7. SWOT Analysis
  • 12.2. AstraZeneca PLC
    • 12.2.1. Business Overview
    • 12.2.2. Financial Overview
    • 12.2.3. Targeted Drug Delivery Portfolio
    • 12.2.4. Pipeline
    • 12.2.5. Technology Platforms
    • 12.2.6. Strategic Developments
    • 12.2.7. SWOT Analysis
  • 12.3. F. Hoffmann-La Roche Ltd
    • 12.3.1. Business Overview
    • 12.3.2. Financial Overview
    • 12.3.3. Targeted Drug Delivery Portfolio
    • 12.3.4. Pipeline
    • 12.3.5. Technology Platforms
    • 12.3.6. Strategic Developments
    • 12.3.7. SWOT Analysis
  • 12.4. Pfizer Inc.
    • 12.4.1. Business Overview
    • 12.4.2. Financial Overview
    • 12.4.3. Targeted Drug Delivery Portfolio
    • 12.4.4. Pipeline
    • 12.4.5. Technology Platforms
    • 12.4.6. Strategic Developments
    • 12.4.7. SWOT Analysis
  • 12.5. Astellas Pharma Inc.
    • 12.5.1. Business Overview
    • 12.5.2. Financial Overview
    • 12.5.3. Targeted Drug Delivery Portfolio
    • 12.5.4. Pipeline
    • 12.5.5. Technology Platforms
    • 12.5.6. Strategic Developments
    • 12.5.7. SWOT Analysis
  • 12.6. Gilead Sciences, Inc.
    • 12.6.1. Business Overview
    • 12.6.2. Financial Overview
    • 12.6.3. Targeted Drug Delivery Portfolio
    • 12.6.4. Pipeline
    • 12.6.5. Technology Platforms
    • 12.6.6. Strategic Developments
    • 12.6.7. SWOT Analysis
  • 12.7. Takeda Pharmaceutical Company Limited
    • 12.7.1. Business Overview
    • 12.7.2. Financial Overview
    • 12.7.3. Targeted Drug Delivery Portfolio
    • 12.7.4. Pipeline
    • 12.7.5. Technology Platforms
    • 12.7.6. Strategic Developments
    • 12.7.7. SWOT Analysis
  • 12.8. GSK plc
    • 12.8.1. Business Overview
    • 12.8.2. Financial Overview
    • 12.8.3. Targeted Drug Delivery Portfolio
    • 12.8.4. Pipeline
    • 12.8.5. Technology Platforms
    • 12.8.6. Strategic Developments
    • 12.8.7. SWOT Analysis
  • 12.9. Genmab A/S
    • 12.9.1. Business Overview
    • 12.9.2. Financial Overview
    • 12.9.3. Targeted Drug Delivery Portfolio
    • 12.9.4. Pipeline
    • 12.9.5. Technology Platforms
    • 12.9.6. Strategic Developments
    • 12.9.7. SWOT Analysis
  • 12.10. Alnylam Pharmaceuticals, Inc.
    • 12.10.1. Business Overview
    • 12.10.2. Financial Overview
    • 12.10.3. Targeted Drug Delivery Portfolio
    • 12.10.4. Pipeline
    • 12.10.5. Technology Platforms
    • 12.10.6. Strategic Developments
    • 12.10.7. SWOT Analysis
  • 12.11. Novartis AG
    • 12.11.1. Business Overview
    • 12.11.2. Financial Overview
    • 12.11.3. Targeted Drug Delivery Portfolio
    • 12.11.4. Pipeline
    • 12.11.5. Technology Platforms
    • 12.11.6. Strategic Developments
    • 12.11.7. SWOT Analysis
  • 12.12. Ionis Pharmaceuticals, Inc.
    • 12.12.1. Business Overview
    • 12.12.2. Financial Overview
    • 12.12.3. Targeted Drug Delivery Portfolio
    • 12.12.4. Pipeline
    • 12.12.5. Technology Platforms
    • 12.12.6. Strategic Developments
    • 12.12.7. SWOT Analysis
  • 12.13. AbbVie Inc.
    • 12.13.1. Business Overview
    • 12.13.2. Financial Overview
    • 12.13.3. Targeted Drug Delivery Portfolio
    • 12.13.4. Pipeline
    • 12.13.5. Technology Platforms
    • 12.13.6. Strategic Developments
    • 12.13.7. SWOT Analysis
  • 12.14. Arrowhead Pharmaceuticals, Inc.
    • 12.14.1. Business Overview
    • 12.14.2. Financial Overview
    • 12.14.3. Targeted Drug Delivery Portfolio
    • 12.14.4. Pipeline
    • 12.14.5. Technology Platforms
    • 12.14.6. Strategic Developments
    • 12.14.7. SWOT Analysis
  • 12.15. Ipsen S.A.
    • 12.15.1. Business Overview
    • 12.15.2. Financial Overview
    • 12.15.3. Targeted Drug Delivery Portfolio
    • 12.15.4. Pipeline
    • 12.15.5. Technology Platforms
    • 12.15.6. Strategic Developments
    • 12.15.7. SWOT Analysis
  • 12.16. Jazz Pharmaceuticals plc
    • 12.16.1. Business Overview
    • 12.16.2. Financial Overview
    • 12.16.3. Targeted Drug Delivery Portfolio
    • 12.16.4. Pipeline
    • 12.16.5. Technology Platforms
    • 12.16.6. Strategic Developments
    • 12.16.7. SWOT Analysis
  • 12.17. ADC Therapeutics SA
    • 12.17.1. Business Overview
    • 12.17.2. Financial Overview
    • 12.17.3. Targeted Drug Delivery Portfolio
    • 12.17.4. Pipeline
    • 12.17.5. Technology Platforms
    • 12.17.6. Strategic Developments
    • 12.17.7. SWOT Analysis
  • 12.18. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
    • 12.18.1. Business Overview
    • 12.18.2. Financial Overview
    • 12.18.3. Targeted Drug Delivery Portfolio
    • 12.18.4. Pipeline
    • 12.18.5. Technology Platforms
    • 12.18.6. Strategic Developments
    • 12.18.7. SWOT Analysis

13. Appendix

  • 13.1. Related Reports
  • 13.2. Customization Options
Show more
Product Code: MRHC - 1042154

LIST OF TABLES

List of Tables

  • Table 1. Key Approved Targeted Drug Delivery Products
  • Table 2. Global Targeted Drug Delivery Market, by Technology, 2024-2036 (USD Million)
  • Table 3. Global Antibody-Drug Conjugates Market, by Country/Region, 2024-2036 (USD Million)
  • Table 4. Global Ligand-Conjugated Oligonucleotides Market, by Country/Region, 2024-2036 (USD Million)
  • Table 5. Global Lipid Nanoparticle Therapeutics Market, by Country/Region, 2024-2036 (USD Million)
  • Table 6. Global Liposomal Drug Delivery Systems Market, by Country/Region, 2024-2036 (USD Million)
  • Table 7. Global Polymeric & Protein-Based Nanoparticles and Micelles Market, by Country/Region, 2024-2036 (USD Million)
  • Table 8. Global Other Targeted Conjugates & Carriers Market, by Country/Region, 2024-2036 (USD Million)
  • Table 9. Global Targeted Drug Delivery Market, by Payload Type, 2024-2036 (USD Million)
  • Table 10. Global Targeted Drug Delivery Market for Cytotoxic Small-Molecule Payloads, by Country/Region, 2024-2036 (USD Million)
  • Table 11. Global Targeted Drug Delivery Market for siRNA, by Country/Region, 2024-2036 (USD Million)
  • Table 12. Global Targeted Drug Delivery Market for Antisense Oligonucleotides, by Country/Region, 2024-2036 (USD Million)
  • Table 13. Global Targeted Drug Delivery Market for mRNA & Gene-Editing Payloads, by Country/Region, 2024-2036 (USD Million)
  • Table 14. Global Targeted Drug Delivery Market for Other Payloads, by Country/Region, 2024-2036 (USD Million)
  • Table 15. Global Targeted Drug Delivery Market, by Application, 2024-2036 (USD Million)
  • Table 16. Global Targeted Drug Delivery Market for Oncology, by Type, 2024-2036 (USD Million)
  • Table 17. Global Targeted Drug Delivery Market for Oncology, by Country/Region, 2024-2036 (USD Million)
  • Table 18. Global Targeted Drug Delivery Market for Genetic & Rare Disorders, by Country/Region, 2024-2036 (USD Million)
  • Table 19. Global Targeted Drug Delivery Market for Cardiovascular & Metabolic Diseases, by Country/Region, 2024-2036 (USD Million)
  • Table 20. Global Targeted Drug Delivery Market for Infectious Diseases, by Country/Region, 2024-2036 (USD Million)
  • Table 21. Global Targeted Drug Delivery Market for Central Nervous System Disorders, by Country/Region, 2024-2036 (USD Million)
  • Table 22. Global Targeted Drug Delivery Market for Other Applications, by Country/Region, 2024-2036 (USD Million)
  • Table 23. Global Targeted Drug Delivery Market, by Route of Administration, 2024-2036 (USD Million)
  • Table 24. Global Intravenous Targeted Drug Delivery Market, by Country/Region, 2024-2036 (USD Million)
  • Table 25. Global Subcutaneous Targeted Drug Delivery Market, by Country/Region, 2024-2036 (USD Million)
  • Table 26. Global Other Routes Targeted Drug Delivery Market, by Country/Region, 2024-2036 (USD Million)
  • Table 27. Global Targeted Drug Delivery Market, by End User, 2024-2036 (USD Million)
  • Table 28. Global Targeted Drug Delivery Market for Hospitals & Specialty Cancer Centers, by Country/Region, 2024-2036 (USD Million)
  • Table 29. Global Targeted Drug Delivery Market for Ambulatory Infusion Centers & Physician Offices, by Country/Region, 2024-2036 (USD Million)
  • Table 30. Global Targeted Drug Delivery Market for Specialty Pharmacies & Home Care Settings, by Country/Region, 2024-2036 (USD Million)
  • Table 31. Global Targeted Drug Delivery Market, by Region, 2024-2036 (USD Million)
  • Table 32. Global Targeted Drug Delivery Market, by Country/Region, 2024-2036 (USD Million)
  • Table 33. North America: Targeted Drug Delivery Market, by Country/Region, 2024-2036 (USD Million)
  • Table 34. North America: Targeted Drug Delivery Market, by Technology, 2024-2036 (USD Million)
  • Table 35. North America: Targeted Drug Delivery Market, by Payload Type, 2024-2036 (USD Million)
  • Table 36. North America: Targeted Drug Delivery Market, by Application, 2024-2036 (USD Million)
  • Table 37. North America: Targeted Drug Delivery Market, by Route of Administration, 2024-2036 (USD Million)
  • Table 38. North America: Targeted Drug Delivery Market, by End User, 2024-2036 (USD Million)
  • Table 39. U.S.: Targeted Drug Delivery Market, by Technology, 2024-2036 (USD Million)
  • Table 40. U.S.: Targeted Drug Delivery Market, by Payload Type, 2024-2036 (USD Million)
  • Table 41. U.S.: Targeted Drug Delivery Market, by Application, 2024-2036 (USD Million)
  • Table 42. U.S.: Targeted Drug Delivery Market, by Route of Administration, 2024-2036 (USD Million)
  • Table 43. U.S.: Targeted Drug Delivery Market, by End User, 2024-2036 (USD Million)
  • Table 44. Canada: Targeted Drug Delivery Market, by Technology, 2024-2036 (USD Million)
  • Table 45. Canada: Targeted Drug Delivery Market, by Payload Type, 2024-2036 (USD Million)
  • Table 46. Canada: Targeted Drug Delivery Market, by Application, 2024-2036 (USD Million)
  • Table 47. Canada: Targeted Drug Delivery Market, by Route of Administration, 2024-2036 (USD Million)
  • Table 48. Canada: Targeted Drug Delivery Market, by End User, 2024-2036 (USD Million)
  • Table 49. Europe: Targeted Drug Delivery Market, by Country/Region, 2024-2036 (USD Million)
  • Table 50. Europe: Targeted Drug Delivery Market, by Technology, 2024-2036 (USD Million)
  • Table 51. Europe: Targeted Drug Delivery Market, by Payload Type, 2024-2036 (USD Million)
  • Table 52. Europe: Targeted Drug Delivery Market, by Application, 2024-2036 (USD Million)
  • Table 53. Europe: Targeted Drug Delivery Market, by Route of Administration, 2024-2036 (USD Million)
  • Table 54. Europe: Targeted Drug Delivery Market, by End User, 2024-2036 (USD Million)
  • Table 55. Germany: Targeted Drug Delivery Market, by Technology, 2024-2036 (USD Million)
  • Table 56. Germany: Targeted Drug Delivery Market, by Payload Type, 2024-2036 (USD Million)
  • Table 57. Germany: Targeted Drug Delivery Market, by Application, 2024-2036 (USD Million)
  • Table 58. Germany: Targeted Drug Delivery Market, by Route of Administration, 2024-2036 (USD Million)
  • Table 59. Germany: Targeted Drug Delivery Market, by End User, 2024-2036 (USD Million)
  • Table 60. France: Targeted Drug Delivery Market, by Technology, 2024-2036 (USD Million)
  • Table 61. France: Targeted Drug Delivery Market, by Payload Type, 2024-2036 (USD Million)
  • Table 62. France: Targeted Drug Delivery Market, by Application, 2024-2036 (USD Million)
  • Table 63. France: Targeted Drug Delivery Market, by Route of Administration, 2024-2036 (USD Million)
  • Table 64. France: Targeted Drug Delivery Market, by End User, 2024-2036 (USD Million)
  • Table 65. U.K.: Targeted Drug Delivery Market, by Technology, 2024-2036 (USD Million)
  • Table 66. U.K.: Targeted Drug Delivery Market, by Payload Type, 2024-2036 (USD Million)
  • Table 67. U.K.: Targeted Drug Delivery Market, by Application, 2024-2036 (USD Million)
  • Table 68. U.K.: Targeted Drug Delivery Market, by Route of Administration, 2024-2036 (USD Million)
  • Table 69. U.K.: Targeted Drug Delivery Market, by End User, 2024-2036 (USD Million)
  • Table 70. Italy: Targeted Drug Delivery Market, by Technology, 2024-2036 (USD Million)
  • Table 71. Italy: Targeted Drug Delivery Market, by Payload Type, 2024-2036 (USD Million)
  • Table 72. Italy: Targeted Drug Delivery Market, by Application, 2024-2036 (USD Million)
  • Table 73. Italy: Targeted Drug Delivery Market, by Route of Administration, 2024-2036 (USD Million)
  • Table 74. Italy: Targeted Drug Delivery Market, by End User, 2024-2036 (USD Million)
  • Table 75. Spain: Targeted Drug Delivery Market, by Technology, 2024-2036 (USD Million)
  • Table 76. Spain: Targeted Drug Delivery Market, by Payload Type, 2024-2036 (USD Million)
  • Table 77. Spain: Targeted Drug Delivery Market, by Application, 2024-2036 (USD Million)
  • Table 78. Spain: Targeted Drug Delivery Market, by Route of Administration, 2024-2036 (USD Million)
  • Table 79. Spain: Targeted Drug Delivery Market, by End User, 2024-2036 (USD Million)
  • Table 80. Switzerland: Targeted Drug Delivery Market, by Technology, 2024-2036 (USD Million)
  • Table 81. Switzerland: Targeted Drug Delivery Market, by Payload Type, 2024-2036 (USD Million)
  • Table 82. Switzerland: Targeted Drug Delivery Market, by Application, 2024-2036 (USD Million)
  • Table 83. Switzerland: Targeted Drug Delivery Market, by Route of Administration, 2024-2036 (USD Million)
  • Table 84. Switzerland: Targeted Drug Delivery Market, by End User, 2024-2036 (USD Million)
  • Table 85. Netherlands: Targeted Drug Delivery Market, by Technology, 2024-2036 (USD Million)
  • Table 86. Netherlands: Targeted Drug Delivery Market, by Payload Type, 2024-2036 (USD Million)
  • Table 87. Netherlands: Targeted Drug Delivery Market, by Application, 2024-2036 (USD Million)
  • Table 88. Netherlands: Targeted Drug Delivery Market, by Route of Administration, 2024-2036 (USD Million)
  • Table 89. Netherlands: Targeted Drug Delivery Market, by End User, 2024-2036 (USD Million)
  • Table 90. Rest of Europe: Targeted Drug Delivery Market, by Technology, 2024-2036 (USD Million)
  • Table 91. Rest of Europe: Targeted Drug Delivery Market, by Payload Type, 2024-2036 (USD Million)
  • Table 92. Rest of Europe: Targeted Drug Delivery Market, by Application, 2024-2036 (USD Million)
  • Table 93. Rest of Europe: Targeted Drug Delivery Market, by Route of Administration, 2024-2036 (USD Million)
  • Table 94. Rest of Europe: Targeted Drug Delivery Market, by End User, 2024-2036 (USD Million)
  • Table 95. Asia-Pacific: Targeted Drug Delivery Market, by Country/Region, 2024-2036 (USD Million)
  • Table 96. Asia-Pacific: Targeted Drug Delivery Market, by Technology, 2024-2036 (USD Million)
  • Table 97. Asia-Pacific: Targeted Drug Delivery Market, by Payload Type, 2024-2036 (USD Million)
  • Table 98. Asia-Pacific: Targeted Drug Delivery Market, by Application, 2024-2036 (USD Million)
  • Table 99. Asia-Pacific: Targeted Drug Delivery Market, by Route of Administration, 2024-2036 (USD Million)
  • Table 100. Asia-Pacific: Targeted Drug Delivery Market, by End User, 2024-2036 (USD Million)
  • Table 101. Japan: Targeted Drug Delivery Market, by Technology, 2024-2036 (USD Million)
  • Table 102. Japan: Targeted Drug Delivery Market, by Payload Type, 2024-2036 (USD Million)
  • Table 103. Japan: Targeted Drug Delivery Market, by Application, 2024-2036 (USD Million)
  • Table 104. Japan: Targeted Drug Delivery Market, by Route of Administration, 2024-2036 (USD Million)
  • Table 105. Japan: Targeted Drug Delivery Market, by End User, 2024-2036 (USD Million)
  • Table 106. China: Targeted Drug Delivery Market, by Technology, 2024-2036 (USD Million)
  • Table 107. China: Targeted Drug Delivery Market, by Payload Type, 2024-2036 (USD Million)
  • Table 108. China: Targeted Drug Delivery Market, by Application, 2024-2036 (USD Million)
  • Table 109. China: Targeted Drug Delivery Market, by Route of Administration, 2024-2036 (USD Million)
  • Table 110. China: Targeted Drug Delivery Market, by End User, 2024-2036 (USD Million)
  • Table 111. South Korea: Targeted Drug Delivery Market, by Technology, 2024-2036 (USD Million)
  • Table 112. South Korea: Targeted Drug Delivery Market, by Payload Type, 2024-2036 (USD Million)
  • Table 113. South Korea: Targeted Drug Delivery Market, by Application, 2024-2036 (USD Million)
  • Table 114. South Korea: Targeted Drug Delivery Market, by Route of Administration, 2024-2036 (USD Million)
  • Table 115. South Korea: Targeted Drug Delivery Market, by End User, 2024-2036 (USD Million)
  • Table 116. Australia: Targeted Drug Delivery Market, by Technology, 2024-2036 (USD Million)
  • Table 117. Australia: Targeted Drug Delivery Market, by Payload Type, 2024-2036 (USD Million)
  • Table 118. Australia: Targeted Drug Delivery Market, by Application, 2024-2036 (USD Million)
  • Table 119. Australia: Targeted Drug Delivery Market, by Route of Administration, 2024-2036 (USD Million)
  • Table 120. Australia: Targeted Drug Delivery Market, by End User, 2024-2036 (USD Million)
  • Table 121. India: Targeted Drug Delivery Market, by Technology, 2024-2036 (USD Million)
  • Table 122. India: Targeted Drug Delivery Market, by Payload Type, 2024-2036 (USD Million)
  • Table 123. India: Targeted Drug Delivery Market, by Application, 2024-2036 (USD Million)
  • Table 124. India: Targeted Drug Delivery Market, by Route of Administration, 2024-2036 (USD Million)
  • Table 125. India: Targeted Drug Delivery Market, by End User, 2024-2036 (USD Million)
  • Table 126. Southeast Asia: Targeted Drug Delivery Market, by Technology, 2024-2036 (USD Million)
  • Table 127. Southeast Asia: Targeted Drug Delivery Market, by Payload Type, 2024-2036 (USD Million)
  • Table 128. Southeast Asia: Targeted Drug Delivery Market, by Application, 2024-2036 (USD Million)
  • Table 129. Southeast Asia: Targeted Drug Delivery Market, by Route of Administration, 2024-2036 (USD Million)
  • Table 130. Southeast Asia: Targeted Drug Delivery Market, by End User, 2024-2036 (USD Million)
  • Table 131. Rest of Asia-Pacific: Targeted Drug Delivery Market, by Technology, 2024-2036 (USD Million)
  • Table 132. Rest of Asia-Pacific: Targeted Drug Delivery Market, by Payload Type, 2024-2036 (USD Million)
  • Table 133. Rest of Asia-Pacific: Targeted Drug Delivery Market, by Application, 2024-2036 (USD Million)
  • Table 134. Rest of Asia-Pacific: Targeted Drug Delivery Market, by Route of Administration, 2024-2036 (USD Million)
  • Table 135. Rest of Asia-Pacific: Targeted Drug Delivery Market, by End User, 2024-2036 (USD Million)
  • Table 136. Latin America: Targeted Drug Delivery Market, by Country/Region, 2024-2036 (USD Million)
  • Table 137. Latin America: Targeted Drug Delivery Market, by Technology, 2024-2036 (USD Million)
  • Table 138. Latin America: Targeted Drug Delivery Market, by Payload Type, 2024-2036 (USD Million)
  • Table 139. Latin America: Targeted Drug Delivery Market, by Application, 2024-2036 (USD Million)
  • Table 140. Latin America: Targeted Drug Delivery Market, by Route of Administration, 2024-2036 (USD Million)
  • Table 141. Latin America: Targeted Drug Delivery Market, by End User, 2024-2036 (USD Million)
  • Table 142. Brazil: Targeted Drug Delivery Market, by Technology, 2024-2036 (USD Million)
  • Table 143. Brazil: Targeted Drug Delivery Market, by Payload Type, 2024-2036 (USD Million)
  • Table 144. Brazil: Targeted Drug Delivery Market, by Application, 2024-2036 (USD Million)
  • Table 145. Brazil: Targeted Drug Delivery Market, by Route of Administration, 2024-2036 (USD Million)
  • Table 146. Brazil: Targeted Drug Delivery Market, by End User, 2024-2036 (USD Million)
  • Table 147. Mexico: Targeted Drug Delivery Market, by Technology, 2024-2036 (USD Million)
  • Table 148. Mexico: Targeted Drug Delivery Market, by Payload Type, 2024-2036 (USD Million)
  • Table 149. Mexico: Targeted Drug Delivery Market, by Application, 2024-2036 (USD Million)
  • Table 150. Mexico: Targeted Drug Delivery Market, by Route of Administration, 2024-2036 (USD Million)
  • Table 151. Mexico: Targeted Drug Delivery Market, by End User, 2024-2036 (USD Million)
  • Table 152. Rest of Latin America: Targeted Drug Delivery Market, by Technology, 2024-2036 (USD Million)
  • Table 153. Rest of Latin America: Targeted Drug Delivery Market, by Payload Type, 2024-2036 (USD Million)
  • Table 154. Rest of Latin America: Targeted Drug Delivery Market, by Application, 2024-2036 (USD Million)
  • Table 155. Rest of Latin America: Targeted Drug Delivery Market, by Route of Administration, 2024-2036 (USD Million)
  • Table 156. Rest of Latin America: Targeted Drug Delivery Market, by End User, 2024-2036 (USD Million)
  • Table 157. Middle East & Africa: Targeted Drug Delivery Market, by Country/Region, 2024-2036 (USD Million)
  • Table 158. Middle East & Africa: Targeted Drug Delivery Market, by Technology, 2024-2036 (USD Million)
  • Table 159. Middle East & Africa: Targeted Drug Delivery Market, by Payload Type, 2024-2036 (USD Million)
  • Table 160. Middle East & Africa: Targeted Drug Delivery Market, by Application, 2024-2036 (USD Million)
  • Table 161. Middle East & Africa: Targeted Drug Delivery Market, by Route of Administration, 2024-2036 (USD Million)
  • Table 162. Middle East & Africa: Targeted Drug Delivery Market, by End User, 2024-2036 (USD Million)
  • Table 163. Saudi Arabia: Targeted Drug Delivery Market, by Technology, 2024-2036 (USD Million)
  • Table 164. Saudi Arabia: Targeted Drug Delivery Market, by Payload Type, 2024-2036 (USD Million)
  • Table 165. Saudi Arabia: Targeted Drug Delivery Market, by Application, 2024-2036 (USD Million)
  • Table 166. Saudi Arabia: Targeted Drug Delivery Market, by Route of Administration, 2024-2036 (USD Million)
  • Table 167. Saudi Arabia: Targeted Drug Delivery Market, by End User, 2024-2036 (USD Million)
  • Table 168. U.A.E.: Targeted Drug Delivery Market, by Technology, 2024-2036 (USD Million)
  • Table 169. U.A.E.: Targeted Drug Delivery Market, by Payload Type, 2024-2036 (USD Million)
  • Table 170. U.A.E.: Targeted Drug Delivery Market, by Application, 2024-2036 (USD Million)
  • Table 171. U.A.E.: Targeted Drug Delivery Market, by Route of Administration, 2024-2036 (USD Million)
  • Table 172. U.A.E.: Targeted Drug Delivery Market, by End User, 2024-2036 (USD Million)
  • Table 173. Israel: Targeted Drug Delivery Market, by Technology, 2024-2036 (USD Million)
  • Table 174. Israel: Targeted Drug Delivery Market, by Payload Type, 2024-2036 (USD Million)
  • Table 175. Israel: Targeted Drug Delivery Market, by Application, 2024-2036 (USD Million)
  • Table 176. Israel: Targeted Drug Delivery Market, by Route of Administration, 2024-2036 (USD Million)
  • Table 177. Israel: Targeted Drug Delivery Market, by End User, 2024-2036 (USD Million)
  • Table 178. South Africa: Targeted Drug Delivery Market, by Technology, 2024-2036 (USD Million)
  • Table 179. South Africa: Targeted Drug Delivery Market, by Payload Type, 2024-2036 (USD Million)
  • Table 180. South Africa: Targeted Drug Delivery Market, by Application, 2024-2036 (USD Million)
  • Table 181. South Africa: Targeted Drug Delivery Market, by Route of Administration, 2024-2036 (USD Million)
  • Table 182. South Africa: Targeted Drug Delivery Market, by End User, 2024-2036 (USD Million)
  • Table 183. Rest of Middle East & Africa: Targeted Drug Delivery Market, by Technology, 2024-2036 (USD Million)
  • Table 184. Rest of Middle East & Africa: Targeted Drug Delivery Market, by Payload Type, 2024-2036 (USD Million)
  • Table 185. Rest of Middle East & Africa: Targeted Drug Delivery Market, by Application, 2024-2036 (USD Million)
  • Table 186. Rest of Middle East & Africa: Targeted Drug Delivery Market, by Route of Administration, 2024-2036 (USD Million)
  • Table 187. Rest of Middle East & Africa: Targeted Drug Delivery Market, by End User, 2024-2036 (USD Million)
  • Table 188. Recent Developments, by Company (2023-2026)
  • Table 189. Targeted Drug Delivery Market: Competitive Benchmarking, by Technology
  • Table 190. Targeted Drug Delivery Market: Competitive Benchmarking, by Payload Type
  • Table 191. Targeted Drug Delivery Market: Competitive Benchmarking, by Commercial & Pipeline Position
  • Table 192. Daiichi Sankyo Company, Limited: Targeted Drug Delivery Portfolio
  • Table 193. Daiichi Sankyo Company, Limited: Strategic Developments (2023-2026)
  • Table 194. AstraZeneca PLC: Targeted Drug Delivery Portfolio
  • Table 195. AstraZeneca PLC: Strategic Developments (2023-2026)
  • Table 196. F. Hoffmann-La Roche Ltd: Targeted Drug Delivery Portfolio
  • Table 197. Pfizer Inc.: Targeted Drug Delivery Portfolio
  • Table 198. Pfizer Inc.: Strategic Developments (2023-2026)
  • Table 199. Astellas Pharma Inc.: Targeted Drug Delivery Portfolio
  • Table 200. Astellas Pharma Inc.: Strategic Developments (2023-2026)
  • Table 201. Gilead Sciences, Inc.: Targeted Drug Delivery Portfolio
  • Table 202. Gilead Sciences, Inc.: Strategic Developments (2023-2026)
  • Table 203. Takeda Pharmaceutical Company Limited: Targeted Drug Delivery Portfolio
  • Table 204. GSK plc: Targeted Drug Delivery Portfolio
  • Table 205. GSK plc: Strategic Developments (2023-2026)
  • Table 206. Genmab A/S: Targeted Drug Delivery Portfolio
  • Table 207. Genmab A/S: Strategic Developments (2023-2026)
  • Table 208. Alnylam Pharmaceuticals, Inc.: Targeted Drug Delivery Portfolio
  • Table 209. Alnylam Pharmaceuticals, Inc.: Strategic Developments (2023-2026)
  • Table 210. Novartis AG: Targeted Drug Delivery Portfolio
  • Table 211. Novartis AG: Strategic Developments (2023-2026)
  • Table 212. Ionis Pharmaceuticals, Inc.: Targeted Drug Delivery Portfolio
  • Table 213. Ionis Pharmaceuticals, Inc.: Strategic Developments (2023-2026)
  • Table 214. AbbVie Inc.: Targeted Drug Delivery Portfolio
  • Table 215. AbbVie Inc.: Strategic Developments (2023-2026)
  • Table 216. Arrowhead Pharmaceuticals, Inc.: Targeted Drug Delivery Portfolio
  • Table 217. Arrowhead Pharmaceuticals, Inc.: Strategic Developments (2023-2026)
  • Table 218. Ipsen S.A.: Targeted Drug Delivery Portfolio
  • Table 219. Ipsen S.A.: Strategic Developments (2023-2026)
  • Table 220. Jazz Pharmaceuticals plc: Targeted Drug Delivery Portfolio
  • Table 221. ADC Therapeutics SA: Targeted Drug Delivery Portfolio
  • Table 222. ADC Therapeutics SA: Strategic Developments (2023-2026)
  • Table 223. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.: Targeted Drug Delivery Portfolio
  • Table 224. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.: Strategic Developments (2023-2026)

LIST OF FIGURES

List of Figures

  • Figure 1. Targeted Drug Delivery Market Ecosystem
  • Figure 2. Currency Conversion Rates Used in the Study (Annual Average Exchange Rates, 2024-2025)
  • Figure 3. Key Stakeholders in the Targeted Drug Delivery Market
  • Figure 4. Research Process
  • Figure 5. Secondary Sources Referenced for This Study
  • Figure 6. Primary Research Techniques
  • Figure 7. Key Executives Interviewed
  • Figure 8. Breakdown of Primary Interviews (Supply-Side & Demand-Side)
  • Figure 9. Market Sizing and Growth Forecast Approach
  • Figure 10. Data Triangulation
  • Figure 11. Global Targeted Drug Delivery Market, by Technology, 2026 vs. 2036 (USD Million)
  • Figure 12. Global Targeted Drug Delivery Market, by Payload Type, 2026 vs. 2036 (USD Million)
  • Figure 13. Global Targeted Drug Delivery Market, by Application, 2026 vs. 2036 (USD Million)
  • Figure 14. Global Targeted Drug Delivery Market, by Route of Administration, 2026 vs. 2036 (USD Million)
  • Figure 15. Global Targeted Drug Delivery Market, by End User, 2026 vs. 2036 (USD Million)
  • Figure 16. Global Targeted Drug Delivery Market, by Geography, 2026 vs. 2036 (USD Million)
  • Figure 17. Components of a Targeted Drug Delivery System
  • Figure 18. Impact Analysis of Market Dynamics
  • Figure 19. Regulatory Framework for Targeted Drug Delivery Products
  • Figure 20. Porter's Five Forces Analysis - Targeted Drug Delivery Market
  • Figure 21. Global Targeted Drug Delivery Market, by Technology, 2026 Share and CAGR (2026-2036)
  • Figure 22. Global Targeted Drug Delivery Market, by Payload Type, 2026 Share and CAGR (2026-2036)
  • Figure 23. Global Targeted Drug Delivery Market, by Application, 2026 Share and CAGR (2026-2036)
  • Figure 24. Global Targeted Drug Delivery Market, by Route of Administration, 2026 Share and CAGR (2026-2036)
  • Figure 25. Global Targeted Drug Delivery Market, by End User, 2026 Share and CAGR (2026-2036)
  • Figure 26. Global Targeted Drug Delivery Market: Top 10 Countries/Sub-regions, 2026 vs. 2036 (USD Million)
  • Figure 27. North America: Targeted Drug Delivery Market Snapshot, 2026-2036 (USD Million)
  • Figure 28. Europe: Targeted Drug Delivery Market Snapshot, 2026-2036 (USD Million)
  • Figure 29. Asia-Pacific: Targeted Drug Delivery Market Snapshot, 2026-2036 (USD Million)
  • Figure 30. Latin America: Targeted Drug Delivery Market Snapshot, 2026-2036 (USD Million)
  • Figure 31. Middle East & Africa: Targeted Drug Delivery Market Snapshot, 2026-2036 (USD Million)
  • Figure 32. Key Growth Strategies Adopted by Leading Market Players (2023-2026)
  • Figure 33. Competitive Dashboard: Targeted Drug Delivery Market
  • Figure 34. Global Targeted Drug Delivery Market Ranking Analysis, by Key Player (2025)
  • Figure 35. Daiichi Sankyo Company, Limited: Financial Snapshot
  • Figure 36. Daiichi Sankyo Company, Limited: SWOT Analysis
  • Figure 37. AstraZeneca PLC: Financial Snapshot
  • Figure 38. AstraZeneca PLC: SWOT Analysis
  • Figure 39. F. Hoffmann-La Roche Ltd: Financial Snapshot
  • Figure 40. F. Hoffmann-La Roche Ltd: SWOT Analysis
  • Figure 41. Pfizer Inc.: SWOT Analysis
  • Figure 42. Astellas Pharma Inc.: Financial Snapshot
  • Figure 43. Astellas Pharma Inc.: SWOT Analysis
  • Figure 44. Gilead Sciences, Inc.: Financial Snapshot
  • Figure 45. Gilead Sciences, Inc.: SWOT Analysis
  • Figure 46. Takeda Pharmaceutical Company Limited: Financial Snapshot
  • Figure 47. Takeda Pharmaceutical Company Limited: SWOT Analysis
  • Figure 48. GSK plc: SWOT Analysis
  • Figure 49. Genmab A/S: Financial Snapshot
  • Figure 50. Genmab A/S: SWOT Analysis
  • Figure 51. Alnylam Pharmaceuticals, Inc.: Financial Snapshot
  • Figure 52. Alnylam Pharmaceuticals, Inc.: SWOT Analysis
  • Figure 53. Novartis AG: Financial Snapshot
  • Figure 54. Novartis AG: SWOT Analysis
  • Figure 55. Ionis Pharmaceuticals, Inc.: Financial Snapshot
  • Figure 56. Ionis Pharmaceuticals, Inc.: SWOT Analysis
  • Figure 57. AbbVie Inc.: Financial Snapshot
  • Figure 58. AbbVie Inc.: SWOT Analysis
  • Figure 59. Arrowhead Pharmaceuticals, Inc.: Financial Snapshot
  • Figure 60. Arrowhead Pharmaceuticals, Inc.: SWOT Analysis
  • Figure 61. Ipsen S.A.: SWOT Analysis
  • Figure 62. Jazz Pharmaceuticals plc: SWOT Analysis
  • Figure 63. ADC Therapeutics SA: Financial Snapshot
  • Figure 64. ADC Therapeutics SA: SWOT Analysis
  • Figure 65. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.: SWOT Analysis
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!